Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and alpha-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. 1996

D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
Life Sciences Department, IIT Research Institute, Chicago, IL 60616, USA.

The activities of the retinoid, N-(4-hydroxyphenyl)-all-trans-retinamide (4-HPR) and the polyamine synthesis inhibitor, alpha-difluoromethylornithine (DFMO), as inhibitors of lymphoma induction in PIM transgenic mice were evaluated. Lymphoma was induced in male PIM mice by a single intraperitoneal injection of 50 mg N-ethyl-N-nitrosourea (ENU) per kg body weight. Continuous dietary administration of 4-HPR (391, 196 or 98 mg/kg diet) or DFMO (1000, 500 or 250 mg/kg diet) was initiated immediately after ENU administration, and was continued until the end of the study at 35 weeks. At 20 weeks post-ENU, the high dose of 4-HPR reduced both lymphoma incidence and associated mortality. However, the protection conferred by 4-HPR represented a delay rather than an inhibition of neoplastic development, since both lymphoma incidence and mortality at study termination were similar in dietary controls and all groups treated with 4-HPR. DFMO had no effect on lymphoma incidence, latency or mortality at any point in the study. These results suggest that 4-HPR or other retinoids may be effective in the prevention of lymphoma induction, whereas inhibition of polyamine biosynthesis does not appear to present a useful mechanistic target for the chemoprevention of lymphoid neoplasia. The PIM transgenic mouse provides a useful in vivo model for the rapid evaluation of chemopreventive agents.

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000518 Eflornithine An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway. Difluoromethylornithine,alpha-Difluoromethylornithine,DL-alpha-Difluoromethylornithine,Eflornithine Hydrochloride,Eflornithine Monohydrochloride, Monohydrate,MDL-71,782 A,Ornidyl,RMI 71782,Vaniqa,alpha-Difluoromethyl Ornithine,DL alpha Difluoromethylornithine,MDL 71,782 A,MDL71,782 A,Ornithine, alpha-Difluoromethyl,alpha Difluoromethyl Ornithine,alpha Difluoromethylornithine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016588 Anticarcinogenic Agents Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. Anti-Carcinogenic Agents,Anti-Carcinogenic Drugs,Anti-Carcinogenic Effect,Anti-Carcinogenic Effects,Anticarcinogenic Drugs,Anticarcinogenic Effect,Anticarcinogenic Effects,Anticarcinogens,Agents, Anti-Carcinogenic,Agents, Anticarcinogenic,Anti Carcinogenic Agents,Anti Carcinogenic Drugs,Anti Carcinogenic Effect,Anti Carcinogenic Effects,Drugs, Anti-Carcinogenic,Drugs, Anticarcinogenic,Effect, Anti-Carcinogenic,Effect, Anticarcinogenic,Effects, Anti-Carcinogenic,Effects, Anticarcinogenic
D017313 Fenretinide A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent. 4-HPR,4-Hydroxyphenylretinamide,Fenretinide, 13-cis-Isomer,Fenretinimide,MCN-R-1967,N-(4-Hydroxyphenyl)-trans-Retinamide,N-(4-Hydroxyphenyl)retinamide,13-cis-Isomer Fenretinide,4 Hydroxyphenylretinamide,Fenretinide, 13 cis Isomer,MCN R 1967,MCNR1967
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
January 1986, Drug metabolism and disposition: the biological fate of chemicals,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
January 1988, Drug metabolism and disposition: the biological fate of chemicals,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
January 1980, Drug metabolism and disposition: the biological fate of chemicals,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
January 1990, Drug metabolism and disposition: the biological fate of chemicals,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
January 1988, Teratogenesis, carcinogenesis, and mutagenesis,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
September 1983, Toxicology and applied pharmacology,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
August 1998, Cancer research,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
September 1999, International journal of oncology,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
January 1983, Nutrition and cancer,
D L McCormick, and W D Johnson, and K V Rao, and T Bowman-Gram, and V E Steele, and R A Lubet, and G J Kelloff
March 1981, Cancer research,
Copied contents to your clipboard!